In conclusion, in this real-world analysis, octogenarians with EGFR-mutated advanced NSCLC treated by EGFR TKI had clinical outcomes and toxicity profile comparable to younger patients in previous studies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.